| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | protein tyrosine kinase binding | 4.11e-07 | 149 | 163 | 10 | GO:1990782 | |
| GeneOntologyMolecularFunction | granulocyte colony-stimulating factor receptor binding | 4.02e-06 | 14 | 163 | 4 | GO:0005130 | |
| GeneOntologyMolecularFunction | GPI anchor binding | 3.36e-05 | 23 | 163 | 4 | GO:0034235 | |
| GeneOntologyMolecularFunction | kinase binding | CASS4 NRG1 HDAC5 FNTA PSG1 PSG3 PSG4 PSG7 PSG9 SGK1 APC NR3C1 CIT ARHGDIA BMPR2 FBXO5 PARP16 DLG3 RAPGEF2 ATP1B1 HTT | 4.27e-05 | 969 | 163 | 21 | GO:0019900 |
| GeneOntologyMolecularFunction | filamin binding | 8.67e-05 | 29 | 163 | 4 | GO:0031005 | |
| GeneOntologyMolecularFunction | Toll-like receptor binding | 8.67e-05 | 29 | 163 | 4 | GO:0035325 | |
| GeneOntologyMolecularFunction | protein kinase binding | CASS4 NRG1 HDAC5 FNTA PSG1 PSG3 PSG4 PSG7 PSG9 SGK1 APC NR3C1 CIT ARHGDIA BMPR2 FBXO5 DLG3 RAPGEF2 ATP1B1 | 9.61e-05 | 873 | 163 | 19 | GO:0019901 |
| GeneOntologyMolecularFunction | bile acid transmembrane transporter activity | 1.64e-04 | 34 | 163 | 4 | GO:0015125 | |
| GeneOntologyMolecularFunction | NAD+-protein-lysine ADP-ribosyltransferase activity | 6.52e-04 | 5 | 163 | 2 | GO:0140804 | |
| GeneOntologyMolecularFunction | glycolipid binding | 6.81e-04 | 49 | 163 | 4 | GO:0051861 | |
| GeneOntologyBiologicalProcess | positive regulation of vasculogenesis | 1.03e-06 | 24 | 161 | 5 | GO:2001214 | |
| GeneOntologyBiologicalProcess | regulation of locomotion | CASS4 NRG1 HDAC5 AKIRIN1 SPI1 PSG1 MYCBP2 PSG3 PSG4 PSG9 SGK1 PECAM1 MINK1 APC LAMA5 ARHGDIA DUOX1 BMPR2 FBXO5 ADAMTS9 TJP1 SUDS3 ANO6 CAPN7 NISCH MACF1 C5 RAPGEF2 | 1.34e-06 | 1327 | 161 | 28 | GO:0040012 |
| GeneOntologyBiologicalProcess | regulation of cell motility | CASS4 NRG1 HDAC5 AKIRIN1 SPI1 PSG1 PSG3 PSG4 PSG9 SGK1 PECAM1 MINK1 APC LAMA5 ARHGDIA DUOX1 BMPR2 FBXO5 ADAMTS9 TJP1 SUDS3 ANO6 CAPN7 NISCH MACF1 C5 RAPGEF2 | 2.14e-06 | 1280 | 161 | 27 | GO:2000145 |
| GeneOntologyBiologicalProcess | regulation of cell migration | CASS4 NRG1 HDAC5 AKIRIN1 SPI1 PSG1 PSG3 PSG4 PSG9 SGK1 PECAM1 MINK1 APC LAMA5 ARHGDIA BMPR2 FBXO5 ADAMTS9 TJP1 SUDS3 ANO6 CAPN7 NISCH MACF1 C5 RAPGEF2 | 2.47e-06 | 1211 | 161 | 26 | GO:0030334 |
| GeneOntologyBiologicalProcess | regulation of vasculogenesis | 2.78e-06 | 29 | 161 | 5 | GO:2001212 | |
| GeneOntologyBiologicalProcess | negative regulation of brown fat cell proliferation | 3.37e-06 | 14 | 161 | 4 | GO:0070348 | |
| GeneOntologyBiologicalProcess | endothelial cell differentiation | 4.28e-06 | 158 | 161 | 9 | GO:0045446 | |
| GeneOntologyBiologicalProcess | regulation of brown fat cell proliferation | 4.57e-06 | 15 | 161 | 4 | GO:0070347 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immune response to tumor cell | 4.57e-06 | 15 | 161 | 4 | GO:0002856 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 4.57e-06 | 15 | 161 | 4 | GO:0002859 | |
| GeneOntologyBiologicalProcess | positive regulation of homophilic cell adhesion | 4.57e-06 | 15 | 161 | 4 | GO:1903387 | |
| GeneOntologyBiologicalProcess | regulation of sprouting angiogenesis | 4.59e-06 | 85 | 161 | 7 | GO:1903670 | |
| GeneOntologyBiologicalProcess | negative regulation of bone resorption | 4.62e-06 | 32 | 161 | 5 | GO:0045779 | |
| GeneOntologyBiologicalProcess | negative regulation of feeding behavior | 5.42e-06 | 33 | 161 | 5 | GO:2000252 | |
| GeneOntologyBiologicalProcess | insulin receptor internalization | 6.05e-06 | 16 | 161 | 4 | GO:0038016 | |
| GeneOntologyBiologicalProcess | negative regulation of vascular permeability | 6.31e-06 | 34 | 161 | 5 | GO:0043116 | |
| GeneOntologyBiologicalProcess | negative regulation of bone remodeling | 6.31e-06 | 34 | 161 | 5 | GO:0046851 | |
| GeneOntologyBiologicalProcess | brown fat cell proliferation | 7.86e-06 | 17 | 161 | 4 | GO:0070342 | |
| GeneOntologyBiologicalProcess | insulin catabolic process | 7.86e-06 | 17 | 161 | 4 | GO:1901143 | |
| GeneOntologyBiologicalProcess | granulocyte colony-stimulating factor signaling pathway | 7.86e-06 | 17 | 161 | 4 | GO:0038158 | |
| GeneOntologyBiologicalProcess | regulation of homophilic cell adhesion | 1.00e-05 | 18 | 161 | 4 | GO:1903385 | |
| GeneOntologyBiologicalProcess | endothelium development | 1.34e-05 | 182 | 161 | 9 | GO:0003158 | |
| GeneOntologyBiologicalProcess | negative regulation of hepatocyte proliferation | 1.57e-05 | 20 | 161 | 4 | GO:2000346 | |
| GeneOntologyBiologicalProcess | negative regulation of fat cell proliferation | 1.93e-05 | 21 | 161 | 4 | GO:0070345 | |
| GeneOntologyBiologicalProcess | negative regulation of response to tumor cell | 1.93e-05 | 21 | 161 | 4 | GO:0002835 | |
| GeneOntologyBiologicalProcess | negative regulation of immune response to tumor cell | 1.93e-05 | 21 | 161 | 4 | GO:0002838 | |
| GeneOntologyBiologicalProcess | response to tumor cell | 1.94e-05 | 71 | 161 | 6 | GO:0002347 | |
| GeneOntologyBiologicalProcess | regulation of vascular permeability | 1.94e-05 | 71 | 161 | 6 | GO:0043114 | |
| GeneOntologyBiologicalProcess | negative regulation of granulocyte differentiation | 2.34e-05 | 22 | 161 | 4 | GO:0030853 | |
| GeneOntologyBiologicalProcess | negative regulation of behavior | 2.59e-05 | 45 | 161 | 5 | GO:0048521 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 2.82e-05 | 23 | 161 | 4 | GO:0002858 | |
| GeneOntologyBiologicalProcess | negative regulation of platelet aggregation | 2.82e-05 | 23 | 161 | 4 | GO:0090331 | |
| GeneOntologyBiologicalProcess | negative regulation of tissue remodeling | 3.20e-05 | 47 | 161 | 5 | GO:0034104 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated immune response to tumor cell | 3.36e-05 | 24 | 161 | 4 | GO:0002855 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated cytotoxicity directed against tumor cell target | 3.36e-05 | 24 | 161 | 4 | GO:0002420 | |
| GeneOntologyBiologicalProcess | common myeloid progenitor cell proliferation | 3.98e-05 | 25 | 161 | 4 | GO:0035726 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated immune response to tumor cell | 3.98e-05 | 25 | 161 | 4 | GO:0002423 | |
| GeneOntologyBiologicalProcess | regulation of fat cell proliferation | 5.46e-05 | 27 | 161 | 4 | GO:0070344 | |
| GeneOntologyBiologicalProcess | negative regulation of homotypic cell-cell adhesion | 6.33e-05 | 28 | 161 | 4 | GO:0034111 | |
| GeneOntologyBiologicalProcess | positive regulation of intracellular signal transduction | NCOA2 CASS4 NRG1 ERBB3 SPI1 FGD2 FNTA PSG1 PSG3 PSG4 PSG9 MINK1 NPSR1 TLR9 SIK3 NR3C1 MBIP BMPR2 FSHR IQCJ-SCHIP1 CTNS RAPGEF2 NFAT5 GEN1 | 7.21e-05 | 1299 | 161 | 24 | GO:1902533 |
| GeneOntologyBiologicalProcess | immune response to tumor cell | 7.54e-05 | 56 | 161 | 5 | GO:0002418 | |
| GeneOntologyBiologicalProcess | negative regulation of platelet activation | 9.55e-05 | 31 | 161 | 4 | GO:0010544 | |
| GeneOntologyBiologicalProcess | granulocyte differentiation | 1.05e-04 | 60 | 161 | 5 | GO:0030851 | |
| GeneOntologyBiologicalProcess | fat cell proliferation | 1.08e-04 | 32 | 161 | 4 | GO:0070341 | |
| GeneOntologyBiologicalProcess | regulation of blood vessel remodeling | 1.08e-04 | 32 | 161 | 4 | GO:0060312 | |
| GeneOntologyBiologicalProcess | regulation of feeding behavior | 1.14e-04 | 61 | 161 | 5 | GO:0060259 | |
| GeneOntologyBiologicalProcess | regulation of granulocyte differentiation | 1.23e-04 | 33 | 161 | 4 | GO:0030852 | |
| GeneOntologyBiologicalProcess | cell-cell junction organization | 1.40e-04 | 246 | 161 | 9 | GO:0045216 | |
| GeneOntologyBiologicalProcess | insulin metabolic process | 1.55e-04 | 35 | 161 | 4 | GO:1901142 | |
| GeneOntologyBiologicalProcess | multicellular organismal-level homeostasis | SART3 SPI1 PSG1 PSG3 PSG4 PSG9 PECAM1 TMEM63B APC TLR9 ARSG TJP1 MTHFD1 FSHR C5 CTNS CADPS2 NFAT5 USH2A HTT | 1.87e-04 | 1043 | 161 | 20 | GO:0048871 |
| GeneOntologyBiologicalProcess | regulation of hepatocyte proliferation | 2.15e-04 | 38 | 161 | 4 | GO:2000345 | |
| GeneOntologyBiologicalProcess | regulation of bone resorption | 2.19e-04 | 70 | 161 | 5 | GO:0045124 | |
| GeneOntologyBiologicalProcess | negative regulation of fatty acid biosynthetic process | 2.38e-04 | 39 | 161 | 4 | GO:0045717 | |
| GeneOntologyBiologicalProcess | dicarboxylic acid biosynthetic process | 2.43e-04 | 16 | 161 | 3 | GO:0043650 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity | 2.63e-04 | 40 | 161 | 4 | GO:0045953 | |
| GeneOntologyBiologicalProcess | ERBB signaling pathway | 2.66e-04 | 160 | 161 | 7 | GO:0038127 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immunity | 2.89e-04 | 41 | 161 | 4 | GO:0002716 | |
| GeneOntologyBiologicalProcess | regulation of osteoclast differentiation | 3.01e-04 | 116 | 161 | 6 | GO:0045670 | |
| GeneOntologyBiologicalProcess | regulation of platelet aggregation | 3.18e-04 | 42 | 161 | 4 | GO:0090330 | |
| GeneOntologyBiologicalProcess | sprouting angiogenesis | 3.43e-04 | 220 | 161 | 8 | GO:0002040 | |
| GeneOntologyBiologicalProcess | positive regulation of intracellular steroid hormone receptor signaling pathway | 3.49e-04 | 18 | 161 | 3 | GO:0033145 | |
| GeneOntologyBiologicalProcess | glucocorticoid mediated signaling pathway | 3.60e-04 | 4 | 161 | 2 | GO:0043402 | |
| GeneOntologyBiologicalProcess | regulation of epithelial cell migration | 3.83e-04 | 344 | 161 | 10 | GO:0010632 | |
| GeneOntologyBiologicalProcess | regulation of bone remodeling | 4.08e-04 | 80 | 161 | 5 | GO:0046850 | |
| GeneOntologyBiologicalProcess | striated muscle tissue development | 4.29e-04 | 349 | 161 | 10 | GO:0014706 | |
| GeneOntologyBiologicalProcess | epithelial cell proliferation involved in liver morphogenesis | 4.52e-04 | 46 | 161 | 4 | GO:0072575 | |
| GeneOntologyBiologicalProcess | hepatocyte proliferation | 4.52e-04 | 46 | 161 | 4 | GO:0072574 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated cytotoxicity | 4.91e-04 | 47 | 161 | 4 | GO:0001911 | |
| GeneOntologyBiologicalProcess | bile acid and bile salt transport | 4.91e-04 | 47 | 161 | 4 | GO:0015721 | |
| GeneOntologyBiologicalProcess | regulation of protein modification process | CASS4 NRG1 FGD2 FNTA PSG1 MYCBP2 PSG3 PSG4 PSG9 PECAM1 DUSP7 APC TLR9 MBIP ZNF416 PPP4R4 BMPR2 FBXO5 FSHR DLG3 CEP295 RAPGEF2 NNT HTT | 5.46e-04 | 1488 | 161 | 24 | GO:0031399 |
| GeneOntologyBiologicalProcess | positive regulation of MAPK cascade | NRG1 SPI1 FGD2 PSG1 PSG3 PSG4 PSG9 MINK1 NPSR1 TLR9 MBIP FSHR RAPGEF2 | 5.58e-04 | 571 | 161 | 13 | GO:0043410 |
| GeneOntologyBiologicalProcess | regulation of immune response to tumor cell | 5.76e-04 | 49 | 161 | 4 | GO:0002837 | |
| GeneOntologyBiologicalProcess | liver morphogenesis | 5.76e-04 | 49 | 161 | 4 | GO:0072576 | |
| GeneOntologyBiologicalProcess | epithelial cell migration | HDAC5 PSG1 PSG3 PSG4 PSG9 PECAM1 APC BMPR2 ADAMTS9 CAPN7 MACF1 | 6.00e-04 | 432 | 161 | 11 | GO:0010631 |
| GeneOntologyBiologicalProcess | blood vessel remodeling | 6.01e-04 | 87 | 161 | 5 | GO:0001974 | |
| GeneOntologyBiologicalProcess | cell junction organization | NRG1 FNTA PSG1 MYCBP2 PSG3 PSG4 MYO9A PSG9 PECAM1 APC LAMA5 NFASC THSD1 TJP1 MACF1 PEAK1 RAPGEF2 CDH17 | 6.15e-04 | 974 | 161 | 18 | GO:0034330 |
| GeneOntologyBiologicalProcess | regulation of response to tumor cell | 6.23e-04 | 50 | 161 | 4 | GO:0002834 | |
| GeneOntologyBiologicalProcess | epithelium migration | HDAC5 PSG1 PSG3 PSG4 PSG9 PECAM1 APC BMPR2 ADAMTS9 CAPN7 MACF1 | 6.36e-04 | 435 | 161 | 11 | GO:0090132 |
| GeneOntologyBiologicalProcess | hydrogen peroxide biosynthetic process | 6.45e-04 | 22 | 161 | 3 | GO:0050665 | |
| GeneOntologyBiologicalProcess | tissue migration | HDAC5 PSG1 PSG3 PSG4 PSG9 PECAM1 APC BMPR2 ADAMTS9 CAPN7 MACF1 | 7.11e-04 | 441 | 161 | 11 | GO:0090130 |
| GeneOntologyBiologicalProcess | negative regulation of cell killing | 7.23e-04 | 52 | 161 | 4 | GO:0031342 | |
| GeneOntologyBiologicalProcess | regulation of blood coagulation | 7.38e-04 | 91 | 161 | 5 | GO:0030193 | |
| GeneOntologyBiologicalProcess | negative regulation of mitotic metaphase/anaphase transition | 7.78e-04 | 53 | 161 | 4 | GO:0045841 | |
| GeneOntologyBiologicalProcess | negative regulation of mitotic sister chromatid segregation | 7.78e-04 | 53 | 161 | 4 | GO:0033048 | |
| GeneOntologyBiologicalProcess | negative regulation of sister chromatid segregation | 7.78e-04 | 53 | 161 | 4 | GO:0033046 | |
| GeneOntologyBiologicalProcess | negative regulation of mitotic sister chromatid separation | 7.78e-04 | 53 | 161 | 4 | GO:2000816 | |
| GeneOntologyBiologicalProcess | regulation of homotypic cell-cell adhesion | 7.78e-04 | 53 | 161 | 4 | GO:0034110 | |
| GeneOntologyBiologicalProcess | regulation of cell growth | NRG1 PSG1 PSG3 PSG4 PSG9 SGK1 SPART NR3C1 ZNF416 BMPR2 MACF1 ZNF639 | 7.96e-04 | 519 | 161 | 12 | GO:0001558 |
| GeneOntologyBiologicalProcess | regulation of hemostasis | 8.14e-04 | 93 | 161 | 5 | GO:1900046 | |
| GeneOntologyBiologicalProcess | circulatory system development | NRG1 ERBB3 STAB2 NRAP HDAC5 SPI1 PSG1 PSG3 PSG4 PSG9 PECAM1 CLIC3 APC NR3C1 ZNF416 BMPR2 ADAMTS9 TJP1 MTHFD1 TNFAIP2 C5 RAPGEF2 ALPK2 | 8.37e-04 | 1442 | 161 | 23 | GO:0072359 |
| GeneOntologyBiologicalProcess | protein localization to cell-cell junction | 8.38e-04 | 24 | 161 | 3 | GO:0150105 | |
| GeneOntologyBiologicalProcess | positive regulation of glucocorticoid receptor signaling pathway | 8.90e-04 | 6 | 161 | 2 | GO:2000324 | |
| GeneOntologyBiologicalProcess | negative regulation of metaphase/anaphase transition of cell cycle | 8.95e-04 | 55 | 161 | 4 | GO:1902100 | |
| GeneOntologyBiologicalProcess | negative regulation of chromosome separation | 8.95e-04 | 55 | 161 | 4 | GO:1905819 | |
| GeneOntologyBiologicalProcess | regulation of cell development | NRG1 HDAC5 SPI1 PSG1 PSG3 PSG4 PSG9 SGK1 APC SPART TLR9 CIT SRRT TSC22D1 BMPR2 FSHR TMEM131L MACF1 RAPGEF2 | 9.22e-04 | 1095 | 161 | 19 | GO:0060284 |
| GeneOntologyBiologicalProcess | regulation of coagulation | 9.40e-04 | 96 | 161 | 5 | GO:0050818 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated immunity | 9.40e-04 | 96 | 161 | 5 | GO:0002704 | |
| GeneOntologyBiologicalProcess | negative regulation of chromosome segregation | 1.02e-03 | 57 | 161 | 4 | GO:0051985 | |
| GeneOntologyBiologicalProcess | bone resorption | 1.08e-03 | 99 | 161 | 5 | GO:0045453 | |
| GeneOntologyBiologicalProcess | cardiac muscle tissue development | 1.10e-03 | 327 | 161 | 9 | GO:0048738 | |
| GeneOntologyCellularComponent | transforming growth factor beta ligand-receptor complex | 6.18e-06 | 16 | 164 | 4 | GO:0070021 | |
| GeneOntologyCellularComponent | lateral plasma membrane | 6.96e-06 | 90 | 164 | 7 | GO:0016328 | |
| GeneOntologyCellularComponent | cell-cell junction | NRAP PSG1 PSG3 PSG4 PSG9 PECAM1 APC NFASC BMPR2 UBA1 TJP1 DLG3 CGNL1 RAPGEF2 ATP1B1 CDH17 | 1.76e-05 | 591 | 164 | 16 | GO:0005911 |
| GeneOntologyCellularComponent | basal plasma membrane | ERBB3 PSG1 PSG3 PSG4 PSG9 TLR9 BMPR2 TJP1 DLG3 ATP1B1 ALPK2 CDH17 | 2.41e-05 | 354 | 164 | 12 | GO:0009925 |
| GeneOntologyCellularComponent | apical plasma membrane | NRG1 ERBB3 PSG1 PSG3 PSG4 PSG9 SI TLR9 DUOX1 BMPR2 TJP1 RAPGEF2 ATP1B1 USH2A | 3.14e-05 | 487 | 164 | 14 | GO:0016324 |
| GeneOntologyCellularComponent | basal part of cell | ERBB3 PSG1 PSG3 PSG4 PSG9 TLR9 BMPR2 TJP1 DLG3 ATP1B1 ALPK2 CDH17 | 4.57e-05 | 378 | 164 | 12 | GO:0045178 |
| GeneOntologyCellularComponent | adherens junction | 4.67e-05 | 212 | 164 | 9 | GO:0005912 | |
| GeneOntologyCellularComponent | basolateral plasma membrane | 4.68e-05 | 320 | 164 | 11 | GO:0016323 | |
| GeneOntologyCellularComponent | apical part of cell | NRG1 ERBB3 PSG1 PSG3 PSG4 MYO7B PSG9 SI TLR9 DUOX1 BMPR2 TJP1 RAPGEF2 ATP1B1 USH2A | 6.88e-05 | 592 | 164 | 15 | GO:0045177 |
| GeneOntologyCellularComponent | anchoring junction | CASS4 NRAP PSG1 PSG3 PSG4 PSG9 PECAM1 APC NFASC THSD1 BMPR2 UBA1 TJP1 DLG3 CGNL1 PEAK1 RAPGEF2 ATP1B1 CDH17 | 2.43e-04 | 976 | 164 | 19 | GO:0070161 |
| GeneOntologyCellularComponent | tight junction | 8.09e-04 | 139 | 164 | 6 | GO:0070160 | |
| MousePheno | decreased susceptibility to Coronaviridae infection induced morbidity/mortality | 1.55e-05 | 17 | 130 | 4 | MP:0031047 | |
| MousePheno | increased skeletal muscle triglyceride level | 3.78e-05 | 21 | 130 | 4 | MP:0031415 | |
| Domain | IGc2 | 5.25e-06 | 235 | 158 | 11 | SM00408 | |
| Domain | Ig_sub2 | 5.25e-06 | 235 | 158 | 11 | IPR003598 | |
| Domain | ig | 3.52e-05 | 190 | 158 | 9 | PF00047 | |
| Domain | Immunoglobulin | 3.52e-05 | 190 | 158 | 9 | IPR013151 | |
| Domain | Ig_2 | 3.55e-05 | 73 | 158 | 6 | PF13895 | |
| Domain | Ig-like_fold | NRG1 PSG1 MYCBP2 PSG3 PSG4 TRA PSG7 PSG9 PECAM1 NFASC CEACAM19 CD3G NFAT5 USH2A HCFC1 GPA33 ALPK2 | 1.03e-04 | 706 | 158 | 17 | IPR013783 |
| Domain | - | NRG1 PSG1 MYCBP2 PSG3 PSG4 PSG7 PSG9 PECAM1 NFASC CEACAM19 CD3G NFAT5 USH2A HCFC1 GPA33 ALPK2 | 1.62e-04 | 663 | 158 | 16 | 2.60.40.10 |
| Domain | AT_hook | 3.07e-04 | 16 | 158 | 3 | PF02178 | |
| Pubmed | Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. | NCOA2 AKIRIN1 MYCBP2 MYO9A MINK1 TMEM63B NFASC TEP1 FOXJ3 TRRAP PPP4R4 CUL5 RANBP17 PHKB KMT2C TSC22D1 BMPR2 FAM120A TJP1 MACF1 TTC17 ANKRD12 RAPGEF2 MED27 NFAT5 GPA33 RAI1 HTT | 5.37e-10 | 1489 | 166 | 28 | 28611215 |
| Pubmed | NCOA2 ZWILCH EXOSC10 APC FAM91A1 DEPDC1 FOXJ3 PHKB KMT2C MTHFD1 CCSER2 ZBTB10 TRAPPC10 TMEM131L MACF1 CEP295 ANKRD12 PEAK1 DOT1L NFAT5 GEN1 TP53BP1 KPNA3 | 2.36e-09 | 1084 | 166 | 23 | 11544199 | |
| Pubmed | 4.51e-09 | 14 | 166 | 5 | 34619794 | ||
| Pubmed | 4.51e-09 | 14 | 166 | 5 | 18454175 | ||
| Pubmed | 4.51e-09 | 14 | 166 | 5 | 9212243 | ||
| Pubmed | SART3 MYO9A MINK1 APC KIAA1549 NFASC CIT CUL5 PHKB SRRT ARHGDIA UBA1 SLC25A12 FAM120A TJP1 MTHFD1 NISCH TRAPPC10 MACF1 DLG3 CGNL1 PEAK1 RAPGEF2 ATP1B1 DNAH6 KPNA3 | 4.88e-09 | 1431 | 166 | 26 | 37142655 | |
| Pubmed | NCOA2 EXOSC10 MYCBP2 BEND3 TRRAP MBIP KMT2C UBA1 TJP1 PEAK1 DOT1L SKA3 MED27 HCFC1 TP53BP1 HTT | 1.02e-08 | 549 | 166 | 16 | 38280479 | |
| Pubmed | 1.38e-08 | 17 | 166 | 5 | 16595723 | ||
| Pubmed | Characterization of cDNA encoding novel pregnancy-specific glycoprotein variants. | 1.73e-08 | 7 | 166 | 4 | 7794280 | |
| Pubmed | Disruption of Nectin-like 1 cell adhesion molecule leads to delayed axonal myelination in the CNS. | 2.57e-08 | 19 | 166 | 5 | 19036974 | |
| Pubmed | 1.07e-07 | 3 | 166 | 3 | 2341148 | ||
| Pubmed | A mouse carcinoembryonic antigen gene family member is a calcium-dependent cell adhesion molecule. | 3.46e-07 | 13 | 166 | 4 | 1985902 | |
| Pubmed | CEACAM1+ myeloid cells control angiogenesis in inflammation. | 3.46e-07 | 13 | 166 | 4 | 19273835 | |
| Pubmed | Mechanism of glucose intolerance in mice with dominant negative mutation of CEACAM1. | 3.46e-07 | 13 | 166 | 4 | 16638824 | |
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 20044046 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 32150576 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 6265583 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 34440862 | ||
| Pubmed | CEACAM1 is a potent regulator of B cell receptor complex-induced activation. | 3.46e-07 | 13 | 166 | 4 | 12832451 | |
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 25406283 | ||
| Pubmed | Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor. | 3.46e-07 | 13 | 166 | 4 | 21670291 | |
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 22162753 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 2702644 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 8380065 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 1279194 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 25724769 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 26374765 | ||
| Pubmed | CEACAM1 deficiency delays important wound healing processes. | 3.46e-07 | 13 | 166 | 4 | 22092845 | |
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 11801635 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 28913658 | ||
| Pubmed | Expression of the Bgp gene and characterization of mouse colon biliary glycoprotein isoforms. | 3.46e-07 | 13 | 166 | 4 | 8500759 | |
| Pubmed | Mouse susceptibility to mouse hepatitis virus infection is linked to viral receptor genotype. | 3.46e-07 | 13 | 166 | 4 | 9343248 | |
| Pubmed | Ceacam1 deletion causes vascular alterations in large vessels. | 3.46e-07 | 13 | 166 | 4 | 23800882 | |
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 19285068 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 21760897 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 1719235 | ||
| Pubmed | Mouse hepatitis virus utilizes two carcinoembryonic antigens as alternative receptors. | 3.46e-07 | 13 | 166 | 4 | 1326665 | |
| Pubmed | Conditional deletion of CEACAM1 in hepatic stellate cells causes their activation. | 3.46e-07 | 13 | 166 | 4 | 39168268 | |
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 8402684 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 16619040 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 29377208 | ||
| Pubmed | Expression of MHV-A59 receptor glycoproteins in susceptible and resistant strains of mice. | 3.46e-07 | 13 | 166 | 4 | 8209741 | |
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 27002145 | ||
| Pubmed | Mice with null mutation of Ceacam I develop nonalcoholic steatohepatitis. | 3.46e-07 | 13 | 166 | 4 | 21949477 | |
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 26219866 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 2133556 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 32521208 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 19406938 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 19621080 | ||
| Pubmed | CEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection. | 3.46e-07 | 13 | 166 | 4 | 29967450 | |
| Pubmed | Expression of newly identified secretory CEACAM1(a) isoforms in the intestinal epithelium. | 3.46e-07 | 13 | 166 | 4 | 19358828 | |
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 16680193 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 1653760 | ||
| Pubmed | Regulation of hepatic fibrosis by carcinoembryonic antigen-related cell adhesion molecule 1. | 3.46e-07 | 13 | 166 | 4 | 34058224 | |
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 10964771 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 32169849 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 22469976 | ||
| Pubmed | CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation. | 3.46e-07 | 13 | 166 | 4 | 21532628 | |
| Pubmed | Structural and Molecular Evidence Suggesting Coronavirus-driven Evolution of Mouse Receptor. | 3.46e-07 | 13 | 166 | 4 | 28035001 | |
| Pubmed | Interaction between altered insulin and lipid metabolism in CEACAM1-inactive transgenic mice. | 3.46e-07 | 13 | 166 | 4 | 15316023 | |
| Pubmed | In vivo adaptation and persistence of Neisseria meningitidis within the nasopharyngeal mucosa. | 3.46e-07 | 13 | 166 | 4 | 23935487 | |
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 15331748 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 22673933 | ||
| Pubmed | Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1. | 3.46e-07 | 13 | 166 | 4 | 22406619 | |
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 7628460 | ||
| Pubmed | Forced Hepatic Overexpression of CEACAM1 Curtails Diet-Induced Insulin Resistance. | 3.46e-07 | 13 | 166 | 4 | 25972571 | |
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 19008452 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 18544705 | ||
| Pubmed | Expression of the mouse hepatitis virus receptor by central nervous system microglia. | 3.46e-07 | 13 | 166 | 4 | 15220458 | |
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 18843289 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 15207636 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 21081647 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 11133662 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 11483763 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 2164599 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 29396368 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 18003729 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 26284027 | ||
| Pubmed | CEACAM1 specifically suppresses B cell receptor signaling-mediated activation. | 3.46e-07 | 13 | 166 | 4 | 33352461 | |
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 38381498 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 20739537 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 1633107 | ||
| Pubmed | The role of CEA-related cell adhesion molecule-1 (CEACAM1) in vascular homeostasis. | 3.46e-07 | 13 | 166 | 4 | 27695943 | |
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 20404914 | ||
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 26911181 | ||
| Pubmed | Hepatic CEACAM1 expression indicates donor liver quality and prevents early transplantation injury. | 3.46e-07 | 13 | 166 | 4 | 32027621 | |
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 30664851 | ||
| Pubmed | Role for hepatic CEACAM1 in regulating fatty acid metabolism along the adipocyte-hepatocyte axis. | 3.46e-07 | 13 | 166 | 4 | 27777319 | |
| Pubmed | 3.46e-07 | 13 | 166 | 4 | 18848945 | ||
| Pubmed | NCOA2 AARS1 EXOSC10 MYCBP2 BEND3 FOXJ3 TRRAP CIT PHF21A KMT2C ARHGDIA UBA1 FAM120A MTHFD1 C1orf52 MED27 HNRNPLL HCFC1 TP53BP1 RAI1 | 3.53e-07 | 1103 | 166 | 20 | 34189442 | |
| Pubmed | 4.83e-07 | 14 | 166 | 4 | 37531413 | ||
| Pubmed | Human CEACAM1-LF regulates lipid storage in HepG2 cells via fatty acid transporter CD36. | 4.83e-07 | 14 | 166 | 4 | 34666041 | |
| Pubmed | SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. | 4.83e-07 | 14 | 166 | 4 | 17081782 | |
| Pubmed | Loss of Ceacam1 promotes prostate cancer progression in Pten haploinsufficient male mice. | 4.83e-07 | 14 | 166 | 4 | 32209360 | |
| Pubmed | 4.83e-07 | 14 | 166 | 4 | 11994468 | ||
| Pubmed | 4.83e-07 | 14 | 166 | 4 | 11850617 | ||
| Pubmed | 4.83e-07 | 14 | 166 | 4 | 20381490 | ||
| Pubmed | CEACAM1 regulates integrin αIIbβ3-mediated functions in platelets. | 4.83e-07 | 14 | 166 | 4 | 26196244 | |
| Pubmed | 4.83e-07 | 14 | 166 | 4 | 8896983 | ||
| Pubmed | 4.83e-07 | 14 | 166 | 4 | 22962327 | ||
| GeneFamily | CD molecules|V-set domain containing|Pregnancy specific glycoproteins | 4.47e-09 | 11 | 116 | 5 | 1315 | |
| GeneFamily | Armadillo repeat containing|Protein phosphatase 1 regulatory subunits | 1.64e-04 | 43 | 116 | 4 | 409 | |
| GeneFamily | Olfactory receptors, family 11 | 4.15e-04 | 23 | 116 | 3 | 159 | |
| GeneFamily | Adenosine receptors|V-set domain containing | 6.42e-04 | 163 | 116 | 6 | 590 | |
| GeneFamily | Tudor domain containing | 1.71e-03 | 37 | 116 | 3 | 780 | |
| GeneFamily | Small leucine rich repeat proteoglycans | 2.58e-03 | 12 | 116 | 2 | 573 | |
| GeneFamily | ATAC complex | 3.04e-03 | 13 | 116 | 2 | 1058 | |
| Coexpression | BYSTROEM_CORRELATED_WITH_IL5_DN | 4.22e-07 | 75 | 162 | 7 | MM605 | |
| Coexpression | ZHANG_BREAST_CANCER_PROGENITORS_DN | 6.79e-07 | 159 | 162 | 9 | MM760 | |
| Coexpression | BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_UP | NRG1 AARS1 HDAC5 FNTA PSG1 PSG4 MYO9A PSG7 PSG9 SIK3 FOXJ3 TSC22D1 TJP1 CCSER2 TTC17 ANKRD12 CTNS NFAT5 CHAC1 | 8.57e-07 | 822 | 162 | 19 | M6782 |
| Coexpression | GSE25123_CTRL_VS_ROSIGLITAZONE_STIM_PPARG_KO_MACROPHAGE_DN | 4.34e-06 | 199 | 162 | 9 | M7998 | |
| Coexpression | TABULA_MURIS_SENIS_SUBCUTANEOUS_ADIPOSE_TISSUE_MYELOID_CELL_AGEING | 9.42e-06 | 219 | 162 | 9 | MM3826 | |
| Coexpression | DACOSTA_UV_RESPONSE_VIA_ERCC3_DN | NCOA2 NRG1 MYCBP2 APC SPART SIK3 NR3C1 FOXJ3 TRRAP PHF21A SLC25A12 CCSER2 TMEM131L MACF1 RAPGEF2 TP53BP1 KPNA3 | 2.40e-05 | 856 | 162 | 17 | M4500 |
| Coexpression | GSE21063_CTRL_VS_ANTI_IGM_STIM_BCELL_NFATC1_KO_3H_DN | 2.42e-05 | 189 | 162 | 8 | M8275 | |
| Coexpression | GSE17974_CTRL_VS_ACT_IL4_AND_ANTI_IL12_72H_CD4_TCELL_UP | 3.02e-05 | 195 | 162 | 8 | M4201 | |
| Coexpression | GSE360_L_DONOVANI_VS_B_MALAYI_LOW_DOSE_MAC_DN | 3.49e-05 | 199 | 162 | 8 | M5240 | |
| Coexpression | GSE3691_IFN_PRODUCING_KILLER_DC_VS_CONVENTIONAL_DC_SPLEEN_UP | 3.62e-05 | 200 | 162 | 8 | M6363 | |
| Coexpression | GSE39820_TGFBETA1_IL6_VS_TGFBETA1_IL6_IL23A_TREATED_CD4_TCELL_UP | 3.62e-05 | 200 | 162 | 8 | M5617 | |
| Coexpression | GIBBONS_GENETIC_MOUSE_MODEL_LUNG_ADENOCARCINOMA_DOWN_IN_METASTASIS | 4.42e-05 | 32 | 162 | 4 | MM2 | |
| Coexpression | LAKE_ADULT_KIDNEY_C2_PODOCYTES | 5.46e-05 | 212 | 162 | 8 | M39221 | |
| Coexpression | OUYANG_PROSTATE_CANCER_MARKERS | 6.34e-05 | 35 | 162 | 4 | MM757 | |
| Coexpression | LIM_MAMMARY_STEM_CELL_DN | NCOA2 ERBB3 PSG1 PSG3 PSG4 PSG9 SNX14 DLG3 TNFAIP2 CGNL1 ATP1B1 | 8.98e-05 | 436 | 162 | 11 | MM1326 |
| ToppCell | TCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_Adenocarcinoma-1|TCGA-Pancreas / Sample_Type by Project: Shred V9 | 3.70e-08 | 186 | 167 | 9 | 03db813598b67b1e08f759758a1c2023396921fa | |
| ToppCell | PND07-Endothelial-Endothelial_blood-vessel-Microvascular_EC-EPC-EPC_G2M|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 6.07e-08 | 197 | 167 | 9 | 1c89d6836eed30c50c765f7dde9cc8ee15c363d2 | |
| ToppCell | 10x5'-GI_small-bowel-Lymphocytic_T_CD4-T_CD4/CD8|GI_small-bowel / Manually curated celltypes from each tissue | 5.75e-07 | 188 | 167 | 8 | ab9b725d6e0cdab8e9ddda6dee09e14730e9a578 | |
| ToppCell | LPS-antiTNF-Unknown|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 5.85e-07 | 129 | 167 | 7 | 739b263296c28554967362060b154f7a95e1341d | |
| ToppCell | LPS-antiTNF-Unknown-Endothelial|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.16e-07 | 130 | 167 | 7 | 615c233c7c2600c1c2bc5cf5b1c501fc474564ef | |
| ToppCell | facs-Liver-Non-hepatocytes-3m|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.01e-07 | 193 | 167 | 8 | 8084fa0ce61f1f4a728423b6b81df04eaa5af5b6 | |
| ToppCell | facs-Brain_Myeloid-Hippocampus|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.58e-07 | 195 | 167 | 8 | a1478021a3ed0e779716393124ca2a7770c433b7 | |
| ToppCell | PND10-Endothelial-Endothelial_blood-vessel-Microvascular_EC-EPC|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 7.88e-07 | 196 | 167 | 8 | 0644bd14a944b9c9759a295dfdd5e67a4775f20a | |
| ToppCell | PND10-Endothelial-Endothelial_blood-vessel-Microvascular_EC-EPC-EPC_G2M|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 7.88e-07 | 196 | 167 | 8 | 20383d576708b7e4bfce3e9fe40548cce496e3cb | |
| ToppCell | facs-Liver-Non-hepatocytes-3m-Endothelial|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.18e-07 | 197 | 167 | 8 | a6aaa6faea348291023f0bc4b0f83fbc67d91da6 | |
| ToppCell | facs-Liver-Non-hepatocytes-3m-Endothelial-endothelial_cell_of_hepatic_sinusoid|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.18e-07 | 197 | 167 | 8 | deefb492b5f0e6014144bd465c4a6ae4206e8739 | |
| ToppCell | facs-Liver-Non-hepatocytes-3m-Endothelial-endothelial_cell_of_hepatic_sinusoid|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.50e-07 | 198 | 167 | 8 | f0f1816a0ed3ae8207442602f5cbe4de0382e4b3 | |
| ToppCell | LPS_anti-TNF-Endothelial-Endothelial-FOXM1|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 8.83e-07 | 199 | 167 | 8 | 98575fcce726589e93fbb4df1aab03e57cb56076 | |
| ToppCell | LPS_only-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS_only / Treatment groups by lineage, cell group, cell type | 9.17e-07 | 200 | 167 | 8 | 2dadf317a42a7e27cc1fac74f91b806c93a57108 | |
| ToppCell | facs-Heart-LV-3m-Endothelial-endothelial_cell_of_endocardium|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.00e-06 | 172 | 167 | 7 | f2c17c49b375b28ad47dc6cabda62f1c238023dd | |
| ToppCell | facs-Heart-LV-3m-Endothelial-endocardial_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.00e-06 | 172 | 167 | 7 | 6ab4f01098dddb789df298ddf97b3c384405ee6c | |
| ToppCell | Adult-Epithelial-alveolar_epithelial_cell_type_1|Adult / Lineage, Cell type, age group and donor | 6.92e-06 | 187 | 167 | 7 | 77f78aec946bc6bd85c29aee9ca978ce49f853a3 | |
| ToppCell | Control-Endothelial-Endothelial-FOXM1|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 7.42e-06 | 189 | 167 | 7 | 1e1499b062d9c647c8f38b0c4e0d871d159be5dd | |
| ToppCell | Adult-Epithelial-alveolar_epithelial_cell_type_1-D231|Adult / Lineage, Cell type, age group and donor | 7.42e-06 | 189 | 167 | 7 | 5a04cb25f8f0447b2cecdb6c3695029281aca26d | |
| ToppCell | Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)|World / Lineage, Cell type, age group and donor | 7.95e-06 | 191 | 167 | 7 | d3733c8c4bda70c4390e5601fdda6188a64be944 | |
| ToppCell | PND01-Epithelial|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 8.80e-06 | 194 | 167 | 7 | d21db5e942966ed44bc78ff50130a201fc627074 | |
| ToppCell | PND01-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 9.09e-06 | 195 | 167 | 7 | 43164511f32e4591cb5399182fbac0b911716233 | |
| ToppCell | PND01-Epithelial-Epithelial_Alveolar|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 9.09e-06 | 195 | 167 | 7 | 9337111d75a487abc02969337718c30b1fe81379 | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_cycling|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 9.40e-06 | 196 | 167 | 7 | 1d2e0b328eb822db7521b5f5724d4bd17c0bad5f | |
| ToppCell | LPS_anti-TNF-Epithelial_alveolar-AT_1-Differentiating_AT2|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 9.72e-06 | 197 | 167 | 7 | 3d13a4f2e86422900ee2194e8a1fd1cf9750d5d3 | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_cycling|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 9.72e-06 | 197 | 167 | 7 | 8b616cde333bdbc0c591035ad9e4949155866245 | |
| ToppCell | Biopsy_Control_(H.)-Epithelial-SCGB3A2+|Biopsy_Control_(H.) / Sample group, Lineage and Cell type | 1.00e-05 | 198 | 167 | 7 | 1fe51f4beca0eef4ff117e6edaa646e35c0f9629 | |
| ToppCell | Bronchial-10x5prime-Epithelial-Epi_alveolar-AT1|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 1.00e-05 | 198 | 167 | 7 | 54228dd9a50616d2022712d162a419ed0327cabd | |
| ToppCell | Parenchymal-NucSeq|Parenchymal / Cell types per location group and 10X technology with lineage, and cell group designations | 1.00e-05 | 198 | 167 | 7 | 1996373bdccc55aac347d349bd22f6aad6d0c668 | |
| ToppCell | Parenchymal-10x5prime-Epithelial-Epi_alveolar-AT1|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 1.04e-05 | 199 | 167 | 7 | aca81a879ef9c196bd1885eff4c63ffe6c9682b7 | |
| ToppCell | LPS-antiTNF-Unknown-Endothelial-Pericyte_2|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.06e-05 | 132 | 167 | 6 | 02491930097b75aaeedab9e8200711b0dc610944 | |
| ToppCell | Parenchymal-NucSeq-Epithelial-Epi_alveolar-Dividing_AT2|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.07e-05 | 200 | 167 | 7 | af3dc76b4507bf4edd265169f5dfbbb8a19eb394 | |
| ToppCell | LPS-antiTNF-Endothelial-Endothelial-FOXM1|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.51e-05 | 163 | 167 | 6 | 5285318c52aa31c9b22dc2ffff078e32e408604d | |
| ToppCell | LPS-IL1RA+antiTNF-Endothelial-Endothelial-FOXM1|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.29e-05 | 169 | 167 | 6 | e0607af8ae8609d43e26ff2a2cab92650bfcd5b7 | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Endothelial-blood_vessel_endothelial_cell_of_kidney-capillary-immature_endothelial_cell-Cycling_Endothelial_Cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 4.58e-05 | 171 | 167 | 6 | c2dbc439af28d4fabb24d57685b75b2e588819b0 | |
| ToppCell | COVID-19-Myeloid-MoAM5,_CCL3L1|COVID-19 / Condition, Lineage and Cell class | 4.89e-05 | 173 | 167 | 6 | 502f888b7684ed39f5c577eedcacf673ae81d39e | |
| ToppCell | PND28-Endothelial-Endothelial_blood-vessel-Microvascular_EC-EPC|PND28 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 5.05e-05 | 174 | 167 | 6 | c6087fd0e036ec7f40f0f8f17d1f6ce13ddb5235 | |
| ToppCell | PND07-Endothelial-Endothelial_blood-vessel-Microvascular_EC-EPC-EPC_prolif|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 5.05e-05 | 174 | 167 | 6 | 66555c610251ea04f968c258e312d720c18e7cde | |
| ToppCell | PND28-Endothelial-Endothelial_blood-vessel-Microvascular_EC-EPC-EPC_G2M|PND28 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 5.05e-05 | 174 | 167 | 6 | 72df66319f6efbd88ecf439013d97409fbf3cb52 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_2|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.05e-05 | 174 | 167 | 6 | b3cd22e717d178269e6d5bd5ed7b2d945cd8ea25 | |
| ToppCell | droplet-Liver-LIVER_HEP-30m-Myeloid-Kupffer_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.55e-05 | 177 | 167 | 6 | 14fb8d182775dfd0e49aa7e4e12543a85b3b8bd6 | |
| ToppCell | Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_1-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor | 5.91e-05 | 179 | 167 | 6 | 4f6ca313b78aa93557937a046c44dcf8bcc9963c | |
| ToppCell | COVID-19-Epithelial_cells-AT1|COVID-19 / group, cell type (main and fine annotations) | 5.91e-05 | 179 | 167 | 6 | a0b33bd69ffdfd5d38d80207fb40058a490aa19e | |
| ToppCell | AT1_cells-Donor_05|World / lung cells shred on cell class, cell subclass, sample id | 6.09e-05 | 180 | 167 | 6 | ff4728782c3ec814ba071cc22b7894abdd9da837 | |
| ToppCell | P03-Epithelial-alveolar_epithelial_cell|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 6.28e-05 | 181 | 167 | 6 | c3dbf8850d3812fbb770798f4cf38908db8bb92b | |
| ToppCell | droplet-Lung-3m-Hematologic-lymphocytic-Proliferating_T_cell-proliferating_T|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 6.28e-05 | 181 | 167 | 6 | 74311aac2fe27dc02a9be3bc20e0c7ef1c239049 | |
| ToppCell | droplet-Lung-3m-Hematologic-lymphocytic-Proliferating_T_cell|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 6.28e-05 | 181 | 167 | 6 | cf13bf7a531a2d40f8d778629cf2431b684f65f3 | |
| ToppCell | droplet-Lung-immune-endo-depleted-3m-Lymphocytic-T_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.48e-05 | 182 | 167 | 6 | 3948422707d6d5e021bcd7158e2eb69143613f62 | |
| ToppCell | droplet-Lung-immune-endo-depleted-3m-Lymphocytic-Proliferating_T|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.48e-05 | 182 | 167 | 6 | fe46819c153a81911864473badc794f243705f98 | |
| ToppCell | COVID-19-lung-AT1|lung / Disease (COVID-19 only), tissue and cell type | 6.68e-05 | 183 | 167 | 6 | 942530449e9c6583705eeb8f6f12621daea57252 | |
| ToppCell | AT1-AT2_cells-Donor_02|World / lung cells shred on cell class, cell subclass, sample id | 6.68e-05 | 183 | 167 | 6 | 6821dca076318115d360ff426eb1218cfe104063 | |
| ToppCell | nucseq-Epithelial-Epithelial_Alveolar-AT1-AT1|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 6.88e-05 | 184 | 167 | 6 | 57c792e6e2fedba25d3350ffe649fd74750b579d | |
| ToppCell | nucseq-Epithelial-Epithelial_Alveolar-AT1|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 6.88e-05 | 184 | 167 | 6 | d7bd0f0c607bade67c99e9fb3578a570298bf926 | |
| ToppCell | Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_1|Children_(3_yrs) / Lineage, Cell type, age group and donor | 7.09e-05 | 185 | 167 | 6 | 1c222f7285d6e3dae0354dc7e853ddc0ea55e63e | |
| ToppCell | COVID-19-Epithelial_cells-Airway_club|COVID-19 / group, cell type (main and fine annotations) | 7.09e-05 | 185 | 167 | 6 | cfe6fd73d817e173fe803bc1683c291d9bcb8608 | |
| ToppCell | CV-Healthy-7|Healthy / Virus stimulation, Condition and Cluster | 7.09e-05 | 185 | 167 | 6 | 1979d189c204f4c2893e3170a514ee7d5523406c | |
| ToppCell | wk_15-18-Epithelial-Distal_epithelial_progenitor-epi-tip_intermediate|wk_15-18 / Celltypes from embryonic and fetal-stage human lung | 7.09e-05 | 185 | 167 | 6 | 636505a3d96f75d951ab42bcf8af6ae07abc732d | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_G2M|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 7.09e-05 | 185 | 167 | 6 | 30e041d6f6e310d64809e9d6d93cd30052972f3b | |
| ToppCell | Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 7.30e-05 | 186 | 167 | 6 | 2ea5ff14861e5f91d0e6a5767c403a24045d715c | |
| ToppCell | Epithelial-alveolar_epithelial_cell_type_1|World / Lineage, Cell type, age group and donor | 7.30e-05 | 186 | 167 | 6 | 09d95daa3387a4814cffaa4b798cc2810c3759d0 | |
| ToppCell | 3'-Adult-Appendix-Endothelial-blood_vessel_EC|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 7.52e-05 | 187 | 167 | 6 | 37d8ee5c8bd6324749e5a2adef1d0482c75da80c | |
| ToppCell | Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)|World / Lineage, Cell type, age group and donor | 7.52e-05 | 187 | 167 | 6 | 81cc8435b2704a9a8287b3f54acaae0f11dd4ac7 | |
| ToppCell | 3'-Adult-Appendix-Endothelial|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 7.52e-05 | 187 | 167 | 6 | ec98d5e480b08854dfd0ba6b1dc6610455f90640 | |
| ToppCell | Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_1-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor | 7.52e-05 | 187 | 167 | 6 | d4b0afd9b92c47c8aa348bbd1af7eb54c3d478f2 | |
| ToppCell | LV-10._Endothelium_II|World / Chamber and Cluster_Paper | 7.52e-05 | 187 | 167 | 6 | 7876dcb4800c2e54874df3d933efb79307a64a97 | |
| ToppCell | PND01-03-samps-Epithelial-Alveolar_epithelial|PND01-03-samps / Age Group, Lineage, Cell class and subclass | 7.52e-05 | 187 | 167 | 6 | 23fe3cdd6cc9b067086a8392d104186d300298ea | |
| ToppCell | 368C-Epithelial_cells-Epithelial-I_(AT1)|368C / Donor, Lineage, Cell class and subclass (all cells) | 7.75e-05 | 188 | 167 | 6 | 9155b9a92496e75646778c025b02947e9e9ec73a | |
| ToppCell | 368C-Epithelial_cells-Epithelial-I_(AT1)-|368C / Donor, Lineage, Cell class and subclass (all cells) | 7.75e-05 | 188 | 167 | 6 | c74771584b3ba9561a99a54bf55a9203ddf8eff8 | |
| ToppCell | COVID-19-Epithelial_cells|COVID-19 / group, cell type (main and fine annotations) | 7.75e-05 | 188 | 167 | 6 | c9cdee6f8d42ee69f5fb335f25084603c511bd29 | |
| ToppCell | facs-Skin-Anagen-3m-Epithelial-actively_dividing_stem_cell|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.98e-05 | 189 | 167 | 6 | bfa3ed1360991a3e32fad133017c413f8adc1eba | |
| ToppCell | facs-Skin-Anagen-3m-Epithelial-keratinocyte_stem_cell|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.98e-05 | 189 | 167 | 6 | 96f10c63656e446b4bb712f012e91ae986f8c2d0 | |
| ToppCell | Macrophages-Cryobiopsy_01|World / lung cells shred on cell class, cell subclass, sample id | 7.98e-05 | 189 | 167 | 6 | c05b4b565c0ce56dbb45fc9503654a2ec1a7e1e9 | |
| ToppCell | RA-10._Endothelium_II|World / Chamber and Cluster_Paper | 7.98e-05 | 189 | 167 | 6 | 75c248b9de5e2fb7a0baa8cdbab516e575cc4394 | |
| ToppCell | RA-10._Endothelium_II|RA / Chamber and Cluster_Paper | 7.98e-05 | 189 | 167 | 6 | c81787a8c662db5d7814c583dd64562857629e81 | |
| ToppCell | E18.5-samps-Epithelial|E18.5-samps / Age Group, Lineage, Cell class and subclass | 8.21e-05 | 190 | 167 | 6 | 90accc078e9a72329a415d5cefe062c4196bb624 | |
| ToppCell | Control-Endothelial-VE_Capillary_B|Endothelial / Disease state, Lineage and Cell class | 8.21e-05 | 190 | 167 | 6 | 7f3f419fffe02934b6f27b697f7a6401072491ed | |
| ToppCell | LAM-Epithelial-AT1|LAM / Condition, Lineage and Cell class | 8.45e-05 | 191 | 167 | 6 | 66875b2ec2c510489407f3e433a90cdf74a15094 | |
| ToppCell | facs-SCAT-Fat-3m-Endothelial-endothelial_cell|SCAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.45e-05 | 191 | 167 | 6 | 6b9bbf4a63d4e9a8075bb06c2aa644fcf4ee88b8 | |
| ToppCell | facs-SCAT-Fat-3m-Endothelial-nan|SCAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.45e-05 | 191 | 167 | 6 | a0018f88f7132477cc467ee15db029a585290595 | |
| ToppCell | Endothelial-D_(cycle)|World / shred on cell class and cell subclass (v4) | 8.45e-05 | 191 | 167 | 6 | 49a4d8f181558e3be9527a8ff9a178f3bb01323c | |
| ToppCell | LAM-Epithelial-AT1|Epithelial / Condition, Lineage and Cell class | 8.45e-05 | 191 | 167 | 6 | 3457e15d1e9b36a78363d46b320c4ec46b40290a | |
| ToppCell | Fetal_brain-fetalBrain_Zhong_nature-GW19|fetalBrain_Zhong_nature / Sample Type, Dataset, Time_group, and Cell type. | 8.45e-05 | 191 | 167 | 6 | b5328733da3d3d77c4f6fc5e2ba2035f8898f172 | |
| ToppCell | E18.5-samps-Epithelial-Alveolar_epithelial|E18.5-samps / Age Group, Lineage, Cell class and subclass | 8.45e-05 | 191 | 167 | 6 | 1cd4d513ac363fdda07030b85a88174d29af3588 | |
| ToppCell | CD8+_Memory_T_cell-CV-7|CD8+_Memory_T_cell / cell class, Virus stimulation and cluster | 8.45e-05 | 191 | 167 | 6 | 9454f642c3621370fa23640b631301346b300950 | |
| ToppCell | Endothelial-Endothelial-D_(cycle)|Endothelial / shred on cell class and cell subclass (v4) | 8.45e-05 | 191 | 167 | 6 | a3c5a913a99f17633c140ec9ece81b73e59e0715 | |
| ToppCell | facs-SCAT-Fat-3m-Endothelial|SCAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.45e-05 | 191 | 167 | 6 | 90f0c193dce267a4f1a9b2501f636dafd0a34cf7 | |
| ToppCell | Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)-D062|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 8.70e-05 | 192 | 167 | 6 | 29f49f00770c991b5f27e4cb701dd2d2d6cb7178 | |
| ToppCell | human_hepatoblastoma-Tumor_cells-T1|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells) | 8.95e-05 | 193 | 167 | 6 | 4b9fa2a4424f8abe63fa7bee78db93dda04ab15f | |
| ToppCell | RV-10._Endothelium_II|World / Chamber and Cluster_Paper | 8.95e-05 | 193 | 167 | 6 | 2531266bc57339d4e2b22a88817008e32b8c1598 | |
| ToppCell | P07-Endothelial-proliferative_endothelial_cell-proliferative_endothelial_cell|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 8.95e-05 | 193 | 167 | 6 | 0f21fb8b35f89f4c1c8109d1a4d3d08a452f9edd | |
| ToppCell | RV-10._Endothelium_II|RV / Chamber and Cluster_Paper | 8.95e-05 | 193 | 167 | 6 | 01c2df9206f1527c578e808978e58196c35e72f5 | |
| ToppCell | P07-Endothelial-proliferative_endothelial_cell|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 8.95e-05 | 193 | 167 | 6 | 1e95ef29357969ee385b4717c0b5a497390ac260 | |
| ToppCell | nucseq-Epithelial-Epithelial_Alveolar|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 9.21e-05 | 194 | 167 | 6 | 53f3e49e91b1096f3226010e2de767efb490dfe4 | |
| ToppCell | PND03-Endothelial-Endothelial_blood-vessel-Microvascular_EC-CAP1|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 9.21e-05 | 194 | 167 | 6 | 44c7d4b75f3b7c9301eba20610e548a01a84ae40 | |
| ToppCell | PND03-Endothelial-Endothelial_blood-vessel-Microvascular_EC-CAP1-CAP1_mature|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 9.21e-05 | 194 | 167 | 6 | 7f24023df47935286f185dd428d48797daf26f49 | |
| ToppCell | PND10-Endothelial-Endothelial_blood-vessel-Microvascular_EC-CAP1|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 9.21e-05 | 194 | 167 | 6 | 1b382508453c5b08fb617f626b230adf3b6cff99 | |
| ToppCell | LV-10._Endothelium_II|LV / Chamber and Cluster_Paper | 9.21e-05 | 194 | 167 | 6 | b6cc849fa08599bff9839ef382d190cc964e273e | |
| ToppCell | PND03-Endothelial-Endothelial_blood-vessel|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 9.21e-05 | 194 | 167 | 6 | f93f5148b136819d87faef89707dbaba07d6c2b5 | |
| ToppCell | normal_Lung-Epithelial_cells-AT1|normal_Lung / Location, Cell class and cell subclass | 9.47e-05 | 195 | 167 | 6 | 569d1ebc5a5aa110a2430b096755ae35354040c4 | |
| ToppCell | wk_15-18-Epithelial-Distal_epithelial-type_II_pneumocyte|wk_15-18 / Celltypes from embryonic and fetal-stage human lung | 9.47e-05 | 195 | 167 | 6 | 0e3aac1b1a1fd483f5fb9a394eb90c0e1ce63542 | |
| Computational | Neighborhood of CDKN1C | 5.00e-06 | 27 | 103 | 5 | GNF2_CDKN1C | |
| Computational | Neighborhood of EGFR | 1.20e-05 | 32 | 103 | 5 | GNF2_EGFR | |
| Computational | Neighborhood of IGFBP1 | 1.89e-05 | 35 | 103 | 5 | GNF2_IGFBP1 | |
| Computational | Neighborhood of MMP11 | 4.70e-05 | 42 | 103 | 5 | GNF2_MMP11 | |
| Computational | Neighborhood of TIMP2 | 7.35e-05 | 46 | 103 | 5 | GNF2_TIMP2 | |
| Computational | Neighborhood of KISS1 | 1.00e-04 | 49 | 103 | 5 | GNF2_KISS1 | |
| Disease | cD177 antigen measurement | 2.34e-06 | 18 | 159 | 4 | EFO_0021866 | |
| Disease | attention deficit hyperactivity disorder, substance abuse, antisocial behaviour measurement | MORC1 TSHZ3 ERBB3 NRAP MINK1 NFASC MBIP PHF21A RANBP17 BMPR2 IQCJ IQCJ-SCHIP1 CADPS2 MED27 NFAT5 USH2A | 7.42e-06 | 801 | 159 | 16 | EFO_0003888, EFO_0007052, MONDO_0002491 |
| Disease | Major Depressive Disorder | 5.49e-05 | 243 | 159 | 8 | C1269683 | |
| Disease | Unipolar Depression | 8.57e-05 | 259 | 159 | 8 | C0041696 | |
| Disease | Intellectual Disability | 1.65e-04 | 447 | 159 | 10 | C3714756 | |
| Disease | pregnancy-specific beta-1-glycoprotein 9 measurement | 1.72e-04 | 4 | 159 | 2 | EFO_0801909 | |
| Disease | Usher syndrome (is_implicated_in) | 1.72e-04 | 4 | 159 | 2 | DOID:0050439 (is_implicated_in) | |
| Disease | pregnancy-specific beta-1-glycoprotein 4 measurement | 4.27e-04 | 6 | 159 | 2 | EFO_0801907 | |
| Disease | Pulmonary Hypertension, Primary, 1, With Hereditary Hemorrhagic Telangiectasia | 5.95e-04 | 7 | 159 | 2 | C3714844 | |
| Disease | Pulmonary Hypertension, Primary, 1 | 5.95e-04 | 7 | 159 | 2 | C4552070 | |
| Disease | PULMONARY HYPERTENSION, PRIMARY, DEXFENFLURAMINE-ASSOCIATED | 5.95e-04 | 7 | 159 | 2 | C1969342 | |
| Disease | Pulmonary Hypertension, Primary, Fenfluramine-Associated | 5.95e-04 | 7 | 159 | 2 | C1969343 | |
| Disease | low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio | 7.78e-04 | 200 | 159 | 6 | EFO_0004611, EFO_0020945 | |
| Disease | Global developmental delay | 7.87e-04 | 133 | 159 | 5 | C0557874 | |
| Disease | triglyceride change measurement, response to long-chain n-3 PUFA dietary supplementation | 7.91e-04 | 8 | 159 | 2 | EFO_0007681, EFO_0009308 | |
| Disease | hypothyroidism | 9.14e-04 | 284 | 159 | 7 | EFO_0004705 | |
| Disease | cholesteryl esters to total lipids in very large HDL percentage | 9.62e-04 | 36 | 159 | 3 | EFO_0022257 | |
| Disease | Schizophrenia | NRG1 ERBB3 NPSR1 APC NFASC NR3C1 TRRAP MTHFD1 DLG3 CGNL1 CADPS2 RAI1 KPNA3 | 1.03e-03 | 883 | 159 | 13 | C0036341 |
| Disease | cholesterol:total lipids ratio, low density lipoprotein cholesterol measurement | 1.12e-03 | 144 | 159 | 5 | EFO_0004611, EFO_0020943 | |
| Disease | granulosa cell tumor (is_marker_for) | 1.54e-03 | 11 | 159 | 2 | DOID:2999 (is_marker_for) | |
| Disease | triglycerides in large LDL measurement | 1.62e-03 | 43 | 159 | 3 | EFO_0022319 | |
| Disease | free cholesterol to total lipids in very small VLDL percentage | 1.62e-03 | 43 | 159 | 3 | EFO_0022290 | |
| Disease | Gastric Adenocarcinoma | 1.85e-03 | 45 | 159 | 3 | C0278701 | |
| Disease | very low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio | 1.93e-03 | 239 | 159 | 6 | EFO_0008317, EFO_0020945 | |
| Disease | epilepsy (implicated_via_orthology) | 1.94e-03 | 163 | 159 | 5 | DOID:1826 (implicated_via_orthology) | |
| Disease | Malignant neoplasm of breast | NCOA2 NID2 NRG1 ERBB3 SIK3 CUL5 PHKB ARHGDIA BMPR2 NISCH MACF1 DNAH9 GEN1 TP53BP1 | 2.08e-03 | 1074 | 159 | 14 | C0006142 |
| Disease | calcium measurement | ZWILCH SGK1 FAM91A1 SIK3 PPP4R4 STAC2 MACF1 CGNL1 FER1L5 KPNA3 | 2.23e-03 | 628 | 159 | 10 | EFO_0004838 |
| Disease | cholesteryl esters to total lipids in IDL percentage | 2.50e-03 | 50 | 159 | 3 | EFO_0022247 | |
| Disease | median neuropathy (biomarker_via_orthology) | 2.52e-03 | 14 | 159 | 2 | DOID:571 (biomarker_via_orthology) | |
| Disease | sulfate measurement | 2.52e-03 | 14 | 159 | 2 | EFO_0007864 | |
| Disease | Mental Depression | 2.62e-03 | 254 | 159 | 6 | C0011570 | |
| Disease | cholesteryl esters to total lipids in very large VLDL percentage | 2.95e-03 | 53 | 159 | 3 | EFO_0022258 | |
| Disease | response to bronchodilator, FEV/FEC ratio | KPNA4 NCOA2 NRG1 NPSR1 KERA SIK3 PPP4R4 IQCJ DHX35 IQCJ-SCHIP1 NNT | 3.02e-03 | 766 | 159 | 11 | EFO_0004713, GO_0097366 |
| Disease | total lipids in medium VLDL | 3.11e-03 | 54 | 159 | 3 | EFO_0022153 | |
| Disease | cholesterol to total lipids in very large VLDL percentage | 3.11e-03 | 54 | 159 | 3 | EFO_0022244 | |
| Disease | very low density lipoprotein cholesterol measurement, cholesteryl esters:total lipids ratio | 3.17e-03 | 264 | 159 | 6 | EFO_0008317, EFO_0020944 | |
| Disease | triglycerides in medium VLDL measurement | 3.28e-03 | 55 | 159 | 3 | EFO_0022155 | |
| Disease | cholesterol to total lipids in large HDL percentage | 3.28e-03 | 55 | 159 | 3 | EFO_0022234 | |
| Disease | Idiopathic pulmonary arterial hypertension | 3.29e-03 | 16 | 159 | 2 | C3203102 | |
| Disease | triglycerides in LDL measurement | 3.45e-03 | 56 | 159 | 3 | EFO_0022320 | |
| Disease | free cholesterol to total lipids in medium VLDL percentage | 3.63e-03 | 57 | 159 | 3 | EFO_0022284 | |
| Disease | Benign neoplasm of stomach | 3.72e-03 | 17 | 159 | 2 | C0153943 | |
| Disease | Neoplasm of uncertain or unknown behavior of stomach | 3.72e-03 | 17 | 159 | 2 | C0496905 | |
| Disease | Carcinoma in situ of stomach | 3.72e-03 | 17 | 159 | 2 | C0154060 | |
| Disease | phosphatidylcholine 40:6 measurement | 3.72e-03 | 17 | 159 | 2 | EFO_0010389 | |
| Disease | Familial primary pulmonary hypertension | 3.72e-03 | 17 | 159 | 2 | C0340543 | |
| Disease | lupus nephritis (is_marker_for) | 3.72e-03 | 17 | 159 | 2 | DOID:0080162 (is_marker_for) | |
| Disease | perinatal necrotizing enterocolitis (biomarker_via_orthology) | 3.72e-03 | 17 | 159 | 2 | DOID:8677 (biomarker_via_orthology) | |
| Disease | triglycerides in IDL measurement | 3.81e-03 | 58 | 159 | 3 | EFO_0022149 | |
| Disease | Alzheimer disease, family history of Alzheimer’s disease | 3.99e-03 | 119 | 159 | 4 | EFO_0009268, MONDO_0004975 | |
| Disease | phospholipids in VLDL measurement | 4.00e-03 | 59 | 159 | 3 | EFO_0022301 | |
| Disease | sinusitis (is_marker_for) | 4.17e-03 | 18 | 159 | 2 | DOID:0050127 (is_marker_for) | |
| Disease | Carcinoma of bladder | 4.17e-03 | 18 | 159 | 2 | C0699885 | |
| Disease | total lipids in VLDL measurement | 4.20e-03 | 60 | 159 | 3 | EFO_0022314 | |
| Disease | cholesterol to total lipids in IDL percentage | 4.20e-03 | 60 | 159 | 3 | EFO_0022233 | |
| Disease | triglycerides in small VLDL measurement | 4.40e-03 | 61 | 159 | 3 | EFO_0022145 | |
| Disease | free cholesterol in very large VLDL measurement | 4.40e-03 | 61 | 159 | 3 | EFO_0022274 | |
| Disease | free cholesterol in VLDL measurement | 4.40e-03 | 61 | 159 | 3 | EFO_0022276 | |
| Disease | Bipolar Disorder | 4.47e-03 | 477 | 159 | 8 | C0005586 | |
| Disease | phospholipids in large VLDL measurement | 4.60e-03 | 62 | 159 | 3 | EFO_0022169 | |
| Disease | triglycerides in medium LDL measurement | 4.60e-03 | 62 | 159 | 3 | EFO_0022322 | |
| Disease | phospholipids in very large VLDL measurement | 4.60e-03 | 62 | 159 | 3 | EFO_0022299 | |
| Disease | inflammatory bowel disease (is_implicated_in) | 4.65e-03 | 19 | 159 | 2 | DOID:0050589 (is_implicated_in) | |
| Disease | Systemic Scleroderma | 4.65e-03 | 19 | 159 | 2 | C0036421 | |
| Disease | age at onset, smoking initiation | 4.65e-03 | 19 | 159 | 2 | EFO_0004847, EFO_0005670 | |
| Disease | Acute Myeloid Leukemia, M1 | 4.75e-03 | 125 | 159 | 4 | C0026998 | |
| Disease | Acute Myeloid Leukemia (AML-M2) | 4.75e-03 | 125 | 159 | 4 | C1879321 | |
| Disease | triglycerides to total lipids in medium VLDL percentage | 4.81e-03 | 63 | 159 | 3 | EFO_0022335 | |
| Disease | cholesterol to total lipids in medium VLDL percentage | 4.81e-03 | 63 | 159 | 3 | EFO_0022239 | |
| Disease | asthma (is_marker_for) | 4.88e-03 | 126 | 159 | 4 | DOID:2841 (is_marker_for) | |
| Disease | pulmonary hypertension (is_marker_for) | 5.03e-03 | 64 | 159 | 3 | DOID:6432 (is_marker_for) | |
| Disease | very low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio | 5.07e-03 | 291 | 159 | 6 | EFO_0008317, EFO_0020946 | |
| Disease | triglycerides in small LDL measurement | 5.25e-03 | 65 | 159 | 3 | EFO_0022323 | |
| Disease | cholesterol in large VLDL measurement | 5.25e-03 | 65 | 159 | 3 | EFO_0021902 | |
| Disease | cholesterol in very large VLDL measurement | 5.25e-03 | 65 | 159 | 3 | EFO_0022230 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| LKTELNNYLSINLPQ | 456 | Q9BXU7 | |
| PTPEQIFQNIKQEYS | 71 | Q9H9L7 | |
| QPLVYNKLTFQLEPN | 261 | P21860 | |
| NKIQLQGLQVLLPDY | 236 | Q76B58 | |
| QPKYLQPLLAVQFTN | 251 | P05026 | |
| QTLLPNDQLYQPLKD | 151 | P09693 | |
| QVLLYEPQVNSPKDF | 646 | Q93034 | |
| LIPRVEQQNTKPNIY | 336 | Q9NQ75 | |
| EQQNTKPNIYDIPKA | 341 | Q9NQ75 | |
| LTVQPLYRPYKQQNQ | 266 | Q96LI9 | |
| IIANAKALPYLQQDP | 1911 | Q15878 | |
| QQQQKLESVPPGTYL | 31 | A0A1B0GUI7 | |
| QQNPKVQKYISFSLP | 261 | Q86TB3 | |
| IKNPVPAQDEALYQQ | 116 | O95833 | |
| LPLYENLNIVEQPVN | 201 | Q96EG1 | |
| SKQNTPQYLASPLDQ | 731 | Q8TEK3 | |
| VTRPAFLYNPLNKQI | 66 | Q8N6N3 | |
| LSYVANQEPGILQQK | 1511 | Q6UB98 | |
| LVTRYIKALNPPQQL | 1116 | Q6DHV5 | |
| QPAQQQQPCLYEIKQ | 106 | Q9Y6H1 | |
| PTQVPLQYNELKLAL | 1251 | O14578 | |
| LLNNPYPSVRQKALN | 2091 | Q5H9R4 | |
| QPLAYPKLQRQKLQN | 181 | Q7Z5J4 | |
| NYVASQPKLAPFVIQ | 91 | Q9H2T7 | |
| PLLNPFIYTLRNKQV | 281 | Q9NZP2 | |
| DAENNIEKYPLNLQP | 31 | Q1A5X6 | |
| NKVLLLSIQNPLYPI | 166 | Q8WVV9 | |
| LQTLLKYPELLSNPQ | 411 | Q17RG1 | |
| PPPENVQLVNQYVSK | 301 | Q02297 | |
| IPFLNPIIYSLRNKQ | 281 | P0DN80 | |
| IAEPFQYPQLNLSQL | 1151 | Q9HCM3 | |
| IKYQNRLAEQQPQPQ | 556 | Q86VD1 | |
| QPPPEYQLTAAELKQ | 241 | Q5T5X7 | |
| NINGTDPIQKYLTPQ | 491 | Q4KMQ2 | |
| PQSTYQPPKEQQQLE | 216 | D6REC4 | |
| IQLQPPQKVNFVLSS | 681 | Q9NRD9 | |
| TYPNITLKDPQNNRI | 136 | Q6IE37 | |
| PDYNQLKKQELQPGT | 1846 | P51610 | |
| VTPLFNPLIYSLQNK | 296 | Q8NH07 | |
| LELDLSYNQLQKIPP | 296 | Q06828 | |
| SYNQLQKIPPVNTNL | 301 | Q06828 | |
| QKIPPVNTNLENLYL | 306 | Q06828 | |
| KDQVEYLVQQNVIPP | 401 | O00505 | |
| YLVQQNVIPPFCNLL | 406 | O00505 | |
| VAPVLYTNINFPNLK | 1651 | Q8NEZ4 | |
| KRYNILNQEQPLAQP | 176 | Q99795 | |
| LNYTLPQDVPQLVKA | 521 | Q86VF7 | |
| QNLPALNSAINPLIY | 316 | Q6W5P4 | |
| PIYPQKADEQLKQSL | 666 | Q2LD37 | |
| KDLVAQTAQPDQPNY | 456 | Q658Y4 | |
| PLFNPIIYSLRNKQI | 281 | Q8NHC7 | |
| KNAIKVPIVINPNAY | 621 | Q9H792 | |
| VPIVINPNAYDNLAI | 626 | Q9H792 | |
| PINDNKEPLNSDVQY | 676 | P16284 | |
| NLNVANLPFPLALYK | 771 | Q8IVU3 | |
| SLEEVINPKQVIPQY | 206 | Q5TB30 | |
| KFQIQPLPQSENKLQ | 71 | Q96BD5 | |
| LSQQQDQKPIFNVIP | 341 | P04150 | |
| AQALSPKLYEPDQLQ | 741 | Q9NZB2 | |
| TPPYLQLQVTEKQVL | 3566 | O15230 | |
| PVQDKTPLYSQLLQA | 96 | Q6P2C8 | |
| YPNITLKDPQNNRIF | 141 | Q6IE36 | |
| KQQQIQPKAYNPETL | 661 | O94916 | |
| TFPQNPVELKALYNQ | 341 | Q9UPN3 | |
| PPKYFVVTNNQLLRV | 251 | Q8N5Y8 | |
| PKESYNVQLQLPARV | 211 | Q14112 | |
| LNNPYVRKALNIPEQ | 341 | P10619 | |
| NVNTQVPYQLIPLHN | 131 | Q9NR21 | |
| PVKAQAQPIQLTDLY | 1161 | O94856 | |
| TKPYQNQQLSIRVPL | 251 | Q9H7U1 | |
| TPADAVLQKPQPQLY | 266 | Q01780 | |
| EPEPQILDFQTQQYK | 316 | Q15067 | |
| LPVQLPGILYNVNKQ | 506 | Q9P2N4 | |
| PQILAKLQKYINNPD | 2851 | Q9C0G6 | |
| KVIGEFLSNQQPYPQ | 2996 | P42858 | |
| LANNPQYKLEVQCPQ | 566 | Q9Y6W3 | |
| NYKPPAQKSIQEIQE | 26 | P52565 | |
| LLQPYDPEKNELNLQ | 151 | Q0VF96 | |
| CLLQIQSPDQYPNKN | 176 | Q9UKT4 | |
| QSPDQYPNKNLLPVL | 181 | Q9UKT4 | |
| TPQQQPQYNLPERDK | 266 | Q9UPW0 | |
| PYAALSIEQQRQKLP | 41 | Q9H5Z1 | |
| NSQYQPIKLQGTLPV | 1121 | P01031 | |
| QPLKALAYVATPQNP | 136 | Q9BUX1 | |
| FNVTKPVEYLNNPII | 461 | Q5T3F8 | |
| DVLPTQIYPLPKQQN | 736 | Q13873 | |
| IKYILNVTPNLPNAF | 271 | Q16829 | |
| QAALYIQKIPEQPQK | 31 | Q7Z692 | |
| QSYKPVPAIQTQKLN | 591 | Q86UW7 | |
| LQQAQLYPIAIFIKP | 731 | Q92796 | |
| EQLQALIPYVLNPSK | 291 | Q6DD88 | |
| PKLQTQQTYSIELQP | 256 | O00462 | |
| QPPQQNYSLAELDEK | 306 | Q9NS73 | |
| NLLATLQAYKPQNPK | 46 | Q6ZST2 | |
| LKEYIQKLPAQAPDQ | 256 | Q7Z6J4 | |
| KLSYPQDNLQPDVNL | 681 | Q17RS7 | |
| LLKYPNGVNPVNSND | 191 | O60931 | |
| NPPLLSQFKVQIDSY | 1051 | Q9NYC9 | |
| YKKLFSDAQPLQPLQ | 626 | Q9UQL6 | |
| NNLLYINPEAFQNLP | 106 | P23945 | |
| INPEAFQNLPNLQYL | 111 | P23945 | |
| SQELNPAKNPSYNLV | 196 | Q12864 | |
| NKYQPIQPIQTSKLE | 656 | Q9C0D2 | |
| KPYITINNLNPRENK | 241 | Q00888 | |
| PIPESVIQNYNKALQ | 276 | Q15020 | |
| QLKILINTFNQKPYP | 26 | A6NLW8 | |
| QYNNLNLKTPVPSDI | 306 | P11586 | |
| KPYITINNLNPRENK | 241 | P11464 | |
| PVVSQFLREKQLPYN | 311 | Q8N9I5 | |
| NPKQVQEYQDLLTPV | 381 | Q93100 | |
| PLLNPFIYTLRNKQV | 281 | A6NL08 | |
| VTPLFNPLIYSLQNK | 296 | Q8NG94 | |
| VTPLFNPLIYSLQNK | 296 | B2RN74 | |
| KPYITINNLNPRENK | 241 | Q16557 | |
| QNPLPLYLSLNVKEN | 456 | Q86XP0 | |
| QQQQQLLPGDRKPLY | 491 | Q8N4C8 | |
| YPAQNPELLNKLSQR | 156 | Q13423 | |
| QIATQPRKSNPVLIY | 4676 | O75445 | |
| ELLNIEKNPQKPQYS | 301 | Q9BZE2 | |
| ENQIPPQILEQEKKY | 356 | Q6NUP7 | |
| LPSLVPQNYTENKNE | 556 | A4FU49 | |
| LPNAYFLLPKVQSIQ | 201 | A2VDJ0 | |
| PQIKDLPQPQIYLNA | 1281 | B5MCY1 | |
| QLYPPIKIFNIINSL | 1996 | A0AVI2 | |
| PSLNKNIPVIEYEQF | 111 | Q9Y2G5 | |
| IPYITINNLNPRENK | 241 | Q00887 | |
| KYPNLLNQLLDLQPS | 291 | P49354 | |
| YDNILNKPLQLKPNI | 306 | O00141 | |
| LYLQNNLIETIPEKP | 76 | O60938 | |
| FLQLAQDPTVPTYKQ | 766 | Q8NDX1 | |
| YKEQSLLQPPTLQLL | 526 | Q9Y2K2 | |
| KYNQLQLEKGQTPPE | 1246 | Q6ZUB1 | |
| QLLPSVAILNQKYAP | 1976 | O75592 | |
| NVNKLNYPPFTPDIL | 521 | P14410 | |
| YQQKQGLQPVPLQAT | 556 | Q15714 | |
| TELQSVQPPQLQQLY | 71 | P17947 | |
| DAENNIEKYPLNLQP | 31 | B3KU38 | |
| KPYITINNLNPRENK | 241 | Q13046 | |
| LPSQNPILKNITDYL | 551 | Q9BXP5 | |
| QDILPKYQDQNFLPK | 461 | Q0P6D6 | |
| QDILPKYQDQNFLPK | 491 | Q0P6D6 | |
| VLPKDQNILPKYQGQ | 516 | Q0P6D6 | |
| QNILPKYQGQDFLPK | 521 | Q0P6D6 | |
| QLPVYKLLPSQNRLQ | 1611 | P25054 | |
| LYNDPNSNPKIVQLL | 46 | O75746 | |
| LEQKAPVFPQQYASQ | 1126 | Q15596 | |
| PNENFQSLYNKELPV | 906 | Q9BXT8 | |
| VYPFSQKLNLTPIQR | 221 | P17032 | |
| AKYRNVLNSQNLQPP | 851 | Q9Y4G8 | |
| VLPNPPQAVNNYKEE | 171 | Q8IX90 | |
| TSLQNDLQEVPKLYP | 101 | Q8N0X7 | |
| VQNLYPNDIINSPKL | 281 | Q03169 | |
| QLPVRPTAVKNLYQS | 511 | Q9H900 | |
| KARNRNQNYLVPSPV | 76 | Q9UID6 | |
| ILSQYPRLLPQQAAN | 1616 | Q99973 | |
| KQFIDSNPNQPLVIL | 846 | P49588 | |
| GLQQPVLNKQLTYVL | 906 | Q9Y5W7 | |
| FDNDPVLYNPLQITK | 261 | Q0IIM8 | |
| LKYNNLTVVPRNLPS | 206 | Q9NR96 | |
| VVKPNIQNPDPAVYQ | 131 | P0DTU3 | |
| YKFLPQENNDLALQP | 301 | Q6ZMT1 | |
| QKIIPPLFSYRLAQQ | 521 | Q9NS62 | |
| PLQLYAVTEQLQQGK | 151 | Q9Y2I1 | |
| LGKQQPENISNPLYE | 2506 | Q8WWQ8 | |
| LEIPPFNKQYTESQL | 1766 | Q12888 | |
| LNLAPLQYQDVPLVN | 646 | Q96AE7 | |
| FKQPAENVNQYLTDP | 656 | P22314 | |
| ALQKNSNPYITPNNR | 351 | Q63HK5 | |
| KYQINNISTVPKAIP | 1601 | Q07157 | |
| ILQPQAIANYEKPNK | 186 | Q9BWM5 | |
| KNIQDYFNPATLPLT | 1546 | Q86YA3 | |
| TKRFIYNIPPNNETN | 581 | Q96DT7 | |
| LIPAVQEPKFPQNYN | 491 | Q14139 | |
| QEPKFPQNYNLVTEN | 496 | Q14139 | |
| VPLNTQSQQPIYSKQ | 991 | P48553 | |
| KPAPAQLNYLLTDEQ | 201 | Q9H7L9 | |
| IPNKQLQPKETQIYI | 576 | Q9Y4A5 | |
| KDQVAYLIQQNVIPP | 401 | O00629 | |
| YLIQQNVIPPFCNLL | 406 | O00629 | |
| NPFQVLPLYTLEQVQ | 106 | Q6PIF6 | |
| FYIPQQDPLKTNSQL | 1421 | B2RTY4 |